Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease, Healthy Non-elderly and Elderly Adults

In brief

This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.

Key facts

Study ID
NCT05363293
Run by
Alzamend Neuro, Inc.
People needed
65
Starts
2022-05-04
Expected to finish
2023-05-15
Last updated by the study team
2025-05-14

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.